Entering text into the input field will update the search result below

Inovio acquires rights to early stage therapies

  • Inovio Pharmaceuticals (NASDAQ:INO) acquires the global (ex-China) rights to therapies for Alzheimer's disease and multiple sclerosis based on the work of DNA researcher Dr. Ben Wang from Fudan University's Shanghai Medical College.
  • The therapies work by generating inducible regulatory T cells (iTreg). The cells are involved in shutting down immune responses after they have successfully eliminated invading organisms. They have potential in preventing autoimmune and inflammatory diseases.
  • No financial terms are disclosed.

Recommended For You

About INO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
INO--
Inovio Pharmaceuticals, Inc.